CN117946941A - Lactobacillus plantarum MY6 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and medicine - Google Patents
Lactobacillus plantarum MY6 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and medicine Download PDFInfo
- Publication number
- CN117946941A CN117946941A CN202410191790.XA CN202410191790A CN117946941A CN 117946941 A CN117946941 A CN 117946941A CN 202410191790 A CN202410191790 A CN 202410191790A CN 117946941 A CN117946941 A CN 117946941A
- Authority
- CN
- China
- Prior art keywords
- strain
- lactobacillus plantarum
- plantarum
- activity
- lactiplantibacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 113
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 113
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 113
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title abstract description 13
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 10
- 235000013305 food Nutrition 0.000 title abstract description 8
- 239000008141 laxative Substances 0.000 title abstract description 4
- 230000002475 laxative effect Effects 0.000 title abstract description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 59
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims abstract description 51
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000006041 probiotic Substances 0.000 claims abstract description 40
- 235000018291 probiotics Nutrition 0.000 claims abstract description 40
- 230000000529 probiotic effect Effects 0.000 claims abstract description 32
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 24
- 108010024636 Glutathione Proteins 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 239000002461 renin inhibitor Substances 0.000 claims description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 6
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 6
- 229940086526 renin-inhibitors Drugs 0.000 claims description 6
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 5
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims description 5
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 74
- 229960003180 glutathione Drugs 0.000 abstract description 26
- 102100033220 Xanthine oxidase Human genes 0.000 abstract description 23
- 108010093894 Xanthine oxidase Proteins 0.000 abstract description 23
- 108090000783 Renin Proteins 0.000 abstract description 20
- 102100028255 Renin Human genes 0.000 abstract description 20
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract description 15
- 229940022698 acetylcholinesterase Drugs 0.000 abstract description 15
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 14
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 14
- 230000000968 intestinal effect Effects 0.000 abstract description 14
- 230000006870 function Effects 0.000 abstract description 13
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000002550 fecal effect Effects 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 230000002040 relaxant effect Effects 0.000 abstract description 5
- 230000032683 aging Effects 0.000 abstract description 4
- 210000000936 intestine Anatomy 0.000 abstract description 4
- 230000008855 peristalsis Effects 0.000 abstract description 4
- 230000002087 whitening effect Effects 0.000 abstract description 4
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 230000031891 intestinal absorption Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 description 33
- 230000004151 fermentation Effects 0.000 description 33
- 239000006228 supernatant Substances 0.000 description 21
- 230000005526 G1 to G0 transition Effects 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 15
- 102100033639 Acetylcholinesterase Human genes 0.000 description 14
- 238000011160 research Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 11
- 241000186660 Lactobacillus Species 0.000 description 9
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 9
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 9
- 229940039696 lactobacillus Drugs 0.000 description 9
- 238000009630 liquid culture Methods 0.000 description 9
- 230000001603 reducing effect Effects 0.000 description 9
- 229940116269 uric acid Drugs 0.000 description 9
- 241000282326 Felis catus Species 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 201000005569 Gout Diseases 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 229910052793 cadmium Inorganic materials 0.000 description 5
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 201000001431 Hyperuricemia Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 3
- 102000005862 Angiotensin II Human genes 0.000 description 3
- 101800000734 Angiotensin-1 Proteins 0.000 description 3
- 102400000344 Angiotensin-1 Human genes 0.000 description 3
- 101800000733 Angiotensin-2 Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 3
- 229950006323 angiotensin ii Drugs 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000003617 erythrocyte membrane Anatomy 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002068 microbial inoculum Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000001775 anti-pathogenic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000001393 triammonium citrate Substances 0.000 description 2
- 235000011046 triammonium citrate Nutrition 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- UPWLZDAZAZFPKZ-UHFFFAOYSA-N 3,3-diethyl-2-benzofuran-1-one Chemical compound C1=CC=C2C(CC)(CC)OC(=O)C2=C1 UPWLZDAZAZFPKZ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 101710178392 Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000003904 glomerular cell Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920003168 pharmaceutical polymer Polymers 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to the technical field of probiotics and application thereof, and particularly relates to lactobacillus plantarum MY6 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and drugs. In order to excavate more lactobacillus plantarum with a probiotic function, the invention separates and purifies a lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain from a fecal sample of a healthy adult in Guangdong area, the strain can generate and secrete 3-hydroxybutyric acid, can inhibit acetylcholinesterase activity, can generate and secrete glutathione, can generate and secrete gamma-aminobutyric acid, can inhibit alpha-glucosidase activity, can inhibit xanthine oxidase activity, can inhibit renin activity, and has the functions of resisting inflammation and improving intestinal flora; promoting intestinal absorption and peristalsis; has the functions of resisting oxidation, whitening skin, delaying aging, resisting inflammation, resisting allergy and the like, and has important potential application value in the fields of resisting inflammation, relaxing the bowels, protecting the intestines and the like.
Description
Technical Field
The invention belongs to the technical field of probiotics and application thereof, and particularly relates to lactobacillus plantarum MY6 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and drugs.
Background
Lactobacillus plantarum (Lactiplantibacillus plantarum), also known as Lactobacillus plantarum, belongs to the genus Lactobacillus of the family Lactobacillus, and is either anaerobic or facultative anaerobic, with an optimal culture pH of 6.5, and the cells are in the form of straight or curved rods, singly, sometimes in pairs or in chains. Lactobacillus plantarum is a probiotic in human gastrointestinal tract, can produce various natural antibacterial substances such as organic acid, bacteriocin, hydrogen peroxide, diethyl phthalide and the like, and has various functions of maintaining balance of intestinal flora, reducing cholesterol level, improving organism immunity, promoting nutrient absorption and the like.
Lactobacillus plantarum is an edible lactobacillus, is closely related to human life, is commonly used in dairy products, meat and fermented products of a plurality of vegetables, can play a beneficial role by being planted in intestinal tracts through stomach, has important influence on intestinal microorganisms, and has wide application in the fields of food fermentation, industrial lactic acid fermentation, medical care and the like. It is well known that lactobacillus is a part of the normal flora of the human body, and is an important component of the normal microbial system of the intestinal tract and is accompanied by a host for life, and has important significance for maintaining the microecological balance of the intestinal tract. The lactobacillus plantarum is also an important intestinal probiotics serving as edible lactobacillus, can play a role in assisting intestinal peristalsis, can also enhance the digestion capacity of a human body, improve immunity and the like. In recent years, lactobacillus plantarum has become a hotspot for research as a probiotic lactobacillus with great potential, and is being continuously made into probiotic preparations suitable for human and animals.
It was found that different strains of lactobacillus plantarum have different probiotic functions, such as: (1) anti-pathogenic bacteria: it has been found that Lactobacillus plantarum has a strong inhibitory effect on Salmonella and on helicobacter pylori. (2) modulating immunity: studies show that the lactobacillus plantarum HK-LP has strong induction effect on IL-12 of mice, and the administration of the HK-LP can inhibit the generation of immunoglobulin, resist food allergy of the mice caused by natural diet, and inhibit the growth of tumors and the transplantation of tumor cells in the bodies of the mice. (3) cadmium removal effect: the research shows that the lactobacillus plantarum CCFM8610 has acid resistance, has good tolerance function and adsorption capacity to cadmium ions in vitro, can reduce the cadmium content in the liver and kidney of the cadmium-exposed mice, and has the effect of promoting the cadmium discharge of the cadmium-exposed mice through feces. (4) inhibition of Escherichia coli: the research shows that the lactobacillus plantarum N13 has acid resistance and cholate resistance, has very high adhesion to the intestinal epithelial cell strain HT-29 cells, can inhibit the growth of intestinal invasive escherichia coli, and can prevent the invasion of the intestinal epithelial cells to HT-29. (5) has proteolytic activity: studies show that the lactobacillus plantarum CW006 has proteolytic activity, and can ferment raw milk to generate angiotensin converting enzyme inhibitory peptide, thereby achieving the antihypertensive effect.
Since lactobacillus plantarum has source diversity, the lactobacillus plantarum has gene diversity and functional diversity, and different lactobacillus plantarum strains have different probiotic functions. At present, although a small part of researches start to pay attention to the development and utilization of lactobacillus plantarum, the researches on the separation and identification, the probiotics characteristics and the metabolic mechanism of the lactobacillus plantarum are still less, and the development and the utilization of the lactobacillus plantarum are affected to a certain extent. Therefore, it is necessary to develop the probiotic function deeply according to different sources of lactobacillus plantarum, so as to define the application prospect, further enrich the number of lactobacillus plantarum and make the lactobacillus plantarum play a larger role in human health. In conclusion, the research and application of the probiotic lactobacillus plantarum have a relatively wide development space.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention obtains the lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain from the fecal sample of a healthy adult in Guangdong area of China through separation and purification, and the strain can generate and secrete 3-hydroxybutyric acid, can inhibit acetylcholinesterase activity, can generate and secrete glutathione, can generate and secrete gamma-aminobutyric acid, can inhibit alpha-glucosidase activity, can inhibit xanthine oxidase activity, can inhibit renin activity, and has important potential application value in the fields of anti-inflammatory, bowel relaxing, and the like.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
The first aspect of the invention provides a lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain, wherein the lactobacillus paracasei MY6 strain is deposited with the China center for type culture collection (China, with accession number: CCTCC NO: M20231172; the whole sequence of the 16S rDNA of the cheese bacillus MY6 strain is shown in SEQ ID No: 1.
In a second aspect, the invention provides the use of a lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain according to the first aspect in the preparation of a renin inhibitor.
The study shows that the probiotics lactobacillus plantarum MY6 strain can effectively inhibit the activity of renin, which suggests that the lactobacillus plantarum MY6 strain can be used as a renin inhibitor for inhibiting the activity of renin, thereby preventing and treating hypertension, other cardiovascular diseases and kidney diseases.
In a third aspect, the invention provides the use of a Lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain according to the first aspect for the production of 3-hydroxybutyric acid.
According to research, the probiotic lactobacillus plantarum MY6 strain can produce 3-hydroxybutyric acid (3-HB), and the probiotic lactobacillus plantarum MY6 strain is suggested to be used for producing 3-HB, and is used for providing energy for various activities of the body, resisting osteoporosis, preventing and treating chronic syndromes, improving brain cognitive functions, improving lipid metabolism, relieving intestinal inflammation and other fields through the characteristic of producing 3-HB.
In a fourth aspect, the invention provides the use of a lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain according to the first aspect in the preparation of an acetylcholinesterase inhibitor.
The research shows that the probiotics lactobacillus plantarum MY6 strain can effectively inhibit the activity of acetylcholinesterase, and the probiotics lactobacillus plantarum MY6 strain is suggested to be used for enhancing the cognition and the memory, dilating blood vessels, exciting skeletal muscles, smooth muscles and other fields by inhibiting the activity of acetylcholinesterase.
In a fifth aspect, the invention provides an application of the Lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain of the first aspect in reduced glutathione production.
The research shows that the probiotics lactobacillus plantarum MY6 strain can produce reduced Glutathione (GSH), which suggests that the lactobacillus plantarum MY6 strain can be used for producing GSH and is used for the fields of antioxidation, whitening, aging delay, immunity enhancement, anti-tumor, antiallergic and the like through the characteristic of GSH production.
In a sixth aspect, the invention provides the use of a lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain according to the first aspect for the production of gamma-aminobutyric acid.
The research shows that the probiotic lactobacillus plantarum MY6 strain can produce gamma-aminobutyric acid (GABA), which suggests that the lactobacillus plantarum MY6 strain can be used for producing GABA and is used for improving the sleeping quality of organisms, resisting depression, resisting anxiety, reducing blood pressure, improving lipid metabolism and other fields by producing GABA.
In a seventh aspect, the invention provides the use of a lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain according to the first aspect in the preparation of an alpha-glucosidase inhibitor.
Through researches, the probiotic lactobacillus plantarum MY6 strain can effectively inhibit the activity of alpha-glucosidase, the alpha-glucosidase is related to type 2 diabetes, and the inhibition of the alpha-glucosidase is one of methods for controlling postprandial hyperglycemia, so that the lactobacillus plantarum MY6 strain is suggested to be expected to be applied to the fields of reducing blood sugar, inhibiting obesity and the like.
According to an eighth aspect of the present invention there is provided the use of a Lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain according to the first aspect in the preparation of a xanthine oxidase inhibitor.
The study shows that the probiotic lactobacillus plantarum MY6 strain can inhibit Xanthine Oxidase (XOD) activity, and the lactobacillus plantarum MY6 strain can be used for inhibiting xanthine oxidase activity, reducing purine in vivo and uric acid generation through the XOD activity, so that uric acid level is controlled, and gout attack is prevented.
In a ninth aspect, the invention provides a probiotic functional bacterial agent, comprising the lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain of the first aspect.
Preferably, the microbial inoculum is a product of lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain after fermentation.
Preferably, the microbial inoculum further comprises auxiliary materials.
More preferably, the adjuvant comprises a carrier and an excipient. The excipient refers to diluents, binders, lubricants, disintegrants, cosolvents, stabilizers and the like which can be used in the pharmaceutical field and some medicinal matrixes. The carrier is a functional pharmaceutical adjuvant available in the pharmaceutical field and comprises a surfactant, a suspending agent, an emulsifying agent and a plurality of novel pharmaceutical polymer materials, such as cyclodextrin, chitosan, polylactic acid (PLA), polyglycolic acid-polylactic acid copolymer (PLGA), hyaluronic acid and the like.
Preferably, in the field of medical application, the dosage forms of the microbial inoculum comprise tablets, granules, capsules, dripping pills, sustained release agents, oral liquid preparations and injections.
More preferably, the above-mentioned dosage forms refer to clinically usual dosage forms. Pharmaceutical formulations may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically), and if some drugs are unstable under gastric conditions, they may be formulated as enteric coated tablets.
Compared with the prior art, the invention has the beneficial effects that:
The invention separates and purifies the excrement sample of a healthy adult in Guangdong area of China to obtain a lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain which has various probiotics effects, including the production and secretion of 3-hydroxybutyric acid, the inhibition of acetylcholinesterase activity, the production and secretion of glutathione, the production and secretion of gamma-aminobutyric acid, the inhibition of alpha-glucosidase activity, the inhibition of xanthine oxidase activity and the inhibition of renin activity. Thus, lactobacillus plantarum MY6 strain has the effect of anti-inflammatory and improving intestinal flora; promoting intestinal absorption and peristalsis; has effects in resisting oxidation, whitening skin, resisting aging, relieving inflammation and resisting allergy; can be used for relieving depression, relieving hangover, and improving sleep; reducing blood glucose; can prevent and relieve hyperuricemia and gout; reducing blood pressure and protecting kidney. Therefore, the lactobacillus plantarum MY6 strain newly separated by the invention has various probiotics effects, can be used in the fields of anti-inflammatory, bowel relaxing, intestine protecting and the like, for example, can be manufactured into anti-inflammatory, bowel relaxing and intestine protecting medicines, and has important application value and economic value.
Drawings
FIG. 1 is a phylogenetic tree of Lactobacillus plantarum MY6 strain (Lactobacillus plantarum JF1 is from Chinese patent "CN116555075B", lactobacillus plantarum JF4 is from Chinese patent "CN116656526B", and the remaining tree building strains are all from Genome database of NCBI);
FIG. 2 shows that Lactobacillus plantarum MY6 strain can produce and secrete 3-hydroxybutyric acid;
FIG. 3 shows that the secretable material of the fermentation broth of Lactobacillus plantarum MY6 significantly inhibits the activity of acetylcholinesterase;
FIG. 4 shows that Lactobacillus plantarum MY6 strain can produce and secrete GSH;
FIG. 5 shows that Lactobacillus plantarum MY6 strain can produce and secrete gamma-aminobutyric acid;
FIG. 6 shows that the secretion of a fermentation broth of Lactobacillus plantarum MY6 significantly inhibits alpha-glucosidase activity;
FIG. 7 shows that Lactobacillus plantarum MY6 strain inhibits XOD activity;
FIG. 8 shows that the secreted substances of Lactobacillus plantarum MY6 fermentation broth significantly inhibited renin activity.
Detailed Description
The following describes the invention in more detail. The description of these embodiments is provided to assist understanding of the present invention, but is not intended to limit the present invention. In addition, the technical features of the embodiments of the present invention described below may be combined with each other as long as they do not collide with each other.
The experimental methods in the following examples, unless otherwise specified, are conventional, and the experimental materials used in the following examples, unless otherwise specified, are commercially available.
The following examples relate to the following experimental materials:
(1) Strains: lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain was committed to a intestinal microbiome study moisturizing laboratory from an intestinal fecal sample isolated from a healthy adult (BMI=19.5) in Guangzhou area of Guangdong, china and placed in a glycerol tube for cryogenic storage at-80 ℃. In general, the strain is inoculated on the surface of a MRS solid culture medium flat plate and is cultured for 24 hours in an inverted manner in a constant temperature anaerobic incubator at 37 ℃ to obtain a bacterial colony, or is cultured for 24-48 hours in a shaking manner in a MRS liquid culture medium in a constant temperature anaerobic incubator at 37 ℃ to obtain a fermentation broth.
(2) The kit comprises: 3-hydroxybutyric acid (3-HB) detection kit (Cloud-Clone Corp., cat: CEB022 Ge), acetylcholinesterase inhibitor screening kit (abnova, cat: KA 6219), micro-reduced Glutathione (GSH) assay kit (Nanjing built, cat: A006-2-1), gamma-aminobutyric acid (GABA) detection kit (Cloud-Clone Corp., cat: CEA900 Ge), alpha-glucosidase inhibitor screening kit (abcam, cat: ab 284520), xanthine oxidase activity assay kit (box manufacturing, cat: AKAO M), renin (Renin) inhibitor screening kit (abnova, cat: KA 1361).
(3) MRS plate: 10g of beef extract, 10g of peptone, 5g of yeast extract, 2g of triammonium citrate, 5g of sodium acetate, 20g of glucose, 2g of dipotassium hydrogen phosphate, 1mL of Tween 80, 0.58g of magnesium sulfate, 0.25g of manganese sulfate, 15g of agar, 1L of ddH 2 O, 6.2-6.6 of pH value, and autoclaving at 121 ℃ for 20min to prepare an MRS plate.
(4) MRS liquid medium: 10g of beef extract, 10g of peptone, 5g of yeast extract, 2g of triammonium citrate, 5g of sodium acetate, 20g of glucose, 2g of dipotassium hydrogen phosphate, 1mL of Tween 80, 0.58g of magnesium sulfate, 0.25g of manganese sulfate, supplementing ddH 2 O to 1L, adjusting the pH to 6.2-6.6, and carrying out high-pressure sterilization at 121 ℃ for 20min to prepare the MRS liquid culture medium.
Example 1 isolation and identification of Lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 Strain
Lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain is isolated from a fecal sample of a healthy adult in Guangdong area of China, and is specifically as follows:
The fecal sample was repeatedly washed 3 times with sterile water, placed in a mortar, 500uL of sterile water was added per 100mg of fecal sample, thoroughly ground to homogenate, and an appropriate amount of the grinding fluid was pipetted, spread on an MRS plate, and incubated at room temperature for 3 days. Colonies to be streaked and purified in the separation assay plates were then numbered with a marker and strain numbers were marked on the plates accordingly. After labelling, colonies were picked and inoculated onto MRS plates and the strains were purified by plate streaking. If the strain cannot be separated by the method, colonies need to be picked from the enrichment plate, and the colonies are coated on a culture medium after being subjected to gradient dilution by MRS liquid culture medium. Finally, reference is made to the "Berger's Manual of bacteria identification" (eighth edition) and the "manual of fungus classification identification", which identify strains belonging to bacteria first. The primary separation is carried out to obtain a purified strain with the strain number MY6, and after 24 hours of culture, white round colony and convex center are observed, and the colony surface is fine and smooth.
Next, the isolated MY6 strain was subjected to molecular characterization by 16S rDNA universal primer (27F: AGAGTTTGATCCTGGCTCAG,1492R: TACGGCTACCTTGTTACGACTT), and then subjected to whole genome sequencing by Beijing Baimaike Biotechnology Co. The resulting 16S rDNA sequence (SEQ ID No: 1) was subjected to BLAST alignment at NCBI' S Genome database. The results showed that the MY6 strain had >99% homology with the known Lactobacillus plantarum (Lactiplantibacillus plantarum) 16S rDNA sequence and was analyzed by evolution with the homologous strain (FIG. 1) to confirm that MY6 was a different strain of Lactobacillus plantarum.
Finally, strain MY6 is preserved with the following information: preservation time: 2023, 7, 3; preservation unit name: china Center for Type Culture Collection (CCTCC); deposit number: CCTCC NO: M20231172; deposit unit address: chinese university of Wuhan; classification naming: lactiplantibacillus plantarum.
Lactobacillus plantarum is a probiotic bacterial strain with wide probiotic effects such as anti-inflammatory, antihypertensive and antipathogenic bacteria, but different sources of bacterial strains have different effects, which indicates that the novel lactobacillus plantarum MY6 bacterial strain separated from a fecal sample of a healthy adult in Guangdong area can be used as a probiotic and possibly has novel effects and functions.
Lactiplantibacillus plantarum MY6 16S rDNA sequence(1437bp，SEQ ID No：1):
GCAGTCGAACGAACTCTGGTATTGATTGGTGCTTGCATCATGATTTACATTTGAGTGAGTGGCGAACTGGTGAGTAACACGTGGGAAACCTGCCCAGAAGCGGGGGATAACACCTGGAAACAGATGCTAATACCGCATAACAACTTGGACCGCATGGTCCGAGTTTGAAAGATGGCTTCGGCTATCACTTTTGGATGGTCCCGCGGCGTATTAGCTAGATGGTGGGGTAACGGCTCACCATGGCAATGATACGTAGCCGACCTGAGAGGGTAATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGAAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAACTCTGTTGTTAAAGAAGAACATATCTGAGAGTAACTGTTCAGGTATTGACGGTATTTAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCTTCGGCTCAACCGAAGAAGTGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCGGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGTATGGGTAGCAAACAGGATTAGATACCCTGGTAGTCCATACCGTAAACGATGAATGCTAAGTGTTGGAGGGTTTCCGCCCTTCAGTGCTGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTACGGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGAACCTTACCAGGTCTTGACATACTATGCAAATCTAAGAGATTAGACGTTCCCTTCGGGGACATGGATACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTATCAGTTGCCAGCATTAAGTTGGGCACTCTGGTGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGATGGTACAACGAGTTGCGAACTCGCGAGAGTAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGATTGTAGGCTGCAACTCGCCTACATGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTTTGTAACACCCAAAGTCGGTGGGGTAACCTTTTAGGAACCAGCCGCCTAA.
Example 2 function of Lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 Strain and application thereof
(1) Lactobacillus plantarum MY6 strain can produce and secrete 3-hydroxybutyric acid (3-HB)
Lactobacillus plantarum MY6 strain cultured with MRS liquid medium to stationary phase was expanded into new MRS liquid medium at dilution ratio of 1:30, bacterial suspension was collected at 24h of stationary phase, and fermentation broth supernatant was collected after centrifugation at 10,000Xg and 4℃for 10min, and then 3-HB concentration of fermentation broth supernatant was measured by 3-HB specific ELISA kit (CEB 022 Ge). The results showed that the concentration of 3-HB in the supernatant of strain MY6 was 0.97. Mu.g/mL, compared to the absence of 3-HB in the blank medium MRS, indicating that Lactobacillus plantarum MY6 can produce and secrete 3-hydroxybutyric acid during the stationary phase (FIG. 2).
3-Hydroxybutyric acid (3-HB) can provide energy for various activities of the body, is a potential energy/functional food, has been added to athlete drinks, and thus the probiotic Lactobacillus plantarum MY6 can be used as an additive to energy foods. Meanwhile, in view of the fact that 3-HB can effectively resist osteoporosis, prevent and treat chronic syndromes (hypertension, alcoholic fatty liver, enteritis and intestinal cancer), improve brain cognitive functions (improving learning and memory capacity, protecting glial cells and improving Alzheimer's disease), and improve lipid metabolism. The probiotic lactobacillus plantarum MY6 strain can exert the functions by producing the effect of 3-hydroxybutyric acid.
In addition, 3-HB is an endogenous small molecule naturally occurring in the body, has an important role in maintaining colorectal tissue integrity, and has the effects of maintaining intestinal health, preventing colonic disease and diminishing inflammation. The 3-HB treatment can promote the proliferation of beneficial intestinal bacteria, relieve the symptoms of multiple sclerosis mice, and has great potential in the aspects of regulating flora and improving health. Therefore, the probiotic lactobacillus plantarum MY6 strain also helps to improve intestinal flora and relieve intestinal inflammation.
(2) The fermentation liquid of the plant lactobacillus MY6 strain can effectively inhibit the activity of acetylcholinesterase
Lactobacillus plantarum MY6 cultured with an MRS liquid medium to a stationary phase is expanded and cultivated into a new MRS liquid medium at a dilution ratio of 1:30, a bacterial suspension is collected when the culture is carried out to the stationary phase for 24 hours, a fermentation broth supernatant is collected after centrifugation at 10,000×g and 4 ℃ for 10 minutes, and then the inhibitory capacity of the fermentation broth supernatant on acetylcholinesterase (AchE) activity is measured by an acetylcholinesterase inhibitor screening kit (KA 6219). The results showed that the fermentation supernatant of strain MY6 significantly inhibited the activity of acetylcholinesterase compared to the non-inhibitory effect of the blank medium MRS, with an inhibition rate of about 59.23%, indicating that the fermentation broth of lactobacillus plantarum MY6 can effectively inhibit the activity of acetylcholinesterase (fig. 3).
Acetylcholinesterase inhibitors allow cholinergic to accumulate at the synapse under the action of acetylcholine released from the nerve fiber tip through reversible inhibition of acetylcholinesterase, excite cholinergic receptors, prolong and augment the action of acetylcholine. Acetylcholinesterase inhibitors can enhance cognitive ability and memory (improve Alzheimer's disease, improve cognitive dysfunction), dilate blood vessels (improve heart rate overspeed), excite skeletal and smooth muscles (improve constipation, postoperative abdominal distension, postoperative urinary retention).
Thus, the probiotic Lactobacillus plantarum MY6 strain can inhibit acetylcholinesterase activity, and excite skeletal and intestinal smooth muscles, which makes it a potential probiotic for promoting gastrointestinal absorption and peristalsis.
(3) Lactobacillus plantarum MY6 strain can produce and secrete reduced Glutathione (GSH)
The Lactobacillus plantarum MY6 strain cultured to the stationary phase by using the MRS liquid culture medium is expanded and cultivated into a new MRS liquid culture medium at a dilution ratio of 1:30, bacterial suspension is collected when the culture is carried out to the stationary phase for 24 hours, fermentation broth supernatant is collected after centrifugation at 10,000Xg and 4 ℃ for 10 minutes, and then the concentration of GSH in the fermentation broth supernatant is measured by using a reduced Glutathione (GSH) measuring kit (A006-2-1). The results show that the concentration of GSH in the fermentation supernatant of strain MY6 was 286.3 μmol/L compared to the low concentration of GSH in the blank medium MRS, suggesting a significant increase in GSH concentration after fermentation with MY6 (< 0.0001) indicating that lactobacillus plantarum MY6 can produce and secrete Glutathione (GSH) during the stationary phase (fig. 4).
Glutathione (GSH) is a tripeptide consisting of glutamic acid, cysteine and glycine, and containing gamma-amide bond and mercapto group, and has antioxidant effect and integrated detoxification effect. The sulfhydryl group on cysteine is a glutathione reactive group (so glutathione is often abbreviated as GSH). Glutathione helps to maintain normal immune system function, has antioxidant and integrated detoxification effects, and plays an important role in various cell biochemical processes, such as free radical neutralization, detoxification, cysteine transport and storage, maintenance of cell redox, ascorbic acid and vitamin E regeneration, and the like. Mainly comprises the following aspects:
① Detoxification: combined with poison or medicine to eliminate its toxic action;
② Participate in the oxidation-reduction reaction: as an important reducing agent, participate in various oxidation-reduction reactions in the body;
③ Protection of thiol enzyme activity: maintaining the active group (-SH) of the sulfhydryl enzyme in a reduced state;
④ Maintenance of the stabilization of erythrocyte membrane structure: eliminating the damage of oxidant to erythrocyte membrane structure.
Thus, the various biological functions of GSH confer a variety of efficacy and utility, primarily represented by:
1) Antioxidant: scavenging free radicals in human bodies, protecting sulfhydryl groups in molecules such as a plurality of proteins, enzymes and the like from being oxidized by harmful substances, thereby ensuring the normal exertion of physiological functions of the proteins, the enzymes and the like; the content of glutathione in human erythrocytes is great, which has important significance for protecting the sulfhydryl group of protein on erythrocyte membrane in a reduced state and preventing hemolysis; it also has effects in preventing skin aging and pigmentation, reducing melanin formation, improving skin antioxidant capacity, and making skin luster.
2) Clinical medicine: the sulfhydryl chelates toxins such as heavy metals, fluoride, mustard gas and the like to prevent poisoning; can also be used as a medicament for treatment or adjuvant therapy in the aspects of hepatitis, hemolytic diseases, keratitis, cataract, retina diseases and the like; can also correct unbalance of acetylcholinesterase and cholinesterase, and has antiallergic effect.
3) Food additives: strengthening food nutrition, stabilizing vitamin C, and strengthening flavor.
In conclusion, the glutathione can be used for medicines and can be used as a base material of functional foods, and has wide application value in the fields of the functional foods such as antioxidation, whitening, aging delaying, immunity enhancing, anti-tumor, antiallergic and the like.
Thus, the probiotic Lactobacillus plantarum MY6 strain can exert the above effects by the function of the GSH produced.
(4) Lactobacillus plantarum MY6 strain can produce and secrete gamma-aminobutyric acid (GABA)
Lactobacillus plantarum MY6 cultured with MRS liquid medium to stationary phase was expanded into new MRS liquid medium at a dilution factor of 1:30, bacterial suspension was collected at 24h of stationary phase, and after centrifugation at 10,000×g at 4 ℃ for 10min, the supernatant of the fermentation broth was collected, and then GABA concentration of the supernatant of the fermentation broth was measured by GABA specific ELISA kit (CEA 900 Ge). The results showed that the concentration of GABA in the fermentation supernatant of strain MY6 was significantly increased compared to the low concentration of GABA in the blank medium MRS, and the accumulated amount was 409.42pg/mL, indicating that lactobacillus plantarum MY6 can produce and secrete gamma-aminobutyric acid in the stationary phase (fig. 5).
Gamma-aminobutyric acid is an important central nervous system inhibitory neurotransmitter, and is widely present in animals, plants and microorganisms. It has been demonstrated that GABA, a small molecular weight non-protein amino acid, is food safe and can be used as a food additive. Research shows that intake of a certain amount of GABA has the physiological effects of improving sleeping quality of organisms, resisting depression, resisting anxiety, reducing blood pressure, improving lipid metabolism, enhancing memory and brain activity, accelerating brain metabolism, strengthening liver and kidney, promoting ethanol metabolism (dispelling alcohol effect), improving climacteric syndrome and the like.
Thus, the probiotic Lactobacillus plantarum MY6 strain can exert the above multiple purposes by the effect of producing gamma-aminobutyric acid.
(5) The fermentation liquor of the plant lactobacillus MY6 strain can effectively inhibit the activity of alpha-glucosidase
Lactobacillus plantarum MY6 cultured to a stationary phase by using an MRS liquid culture medium is expanded and cultured into a new MRS liquid culture medium at a dilution ratio of 1:30, bacterial suspension is collected when the culture is carried out to the stationary phase for 24 hours, fermentation broth supernatant is collected after centrifugation at 10,000Xg and 4 ℃ for 10 minutes, and then the influence of the fermentation broth supernatant on the enzyme activity ability of alpha-glucosidase to hydrolyze glucose is measured by an alpha-glucosidase inhibitor screening kit (ab 284520). The results show that the fermentation supernatant of strain MY6 significantly inhibited the ability of alpha-glucosidase to hydrolyze glucose compared to the non-inhibitory effect of the blank medium MRS, with an inhibition rate of about 64.89%, indicating that the fermentation broth of Lactobacillus plantarum MY6 can effectively inhibit the activity of alpha-glucosidase (FIG. 6).
A-glucosidase, an enzyme that plays a role in carbohydrate breakdown, is associated with type 2 diabetes, and inhibition of α -glucosidase is one of the methods of controlling postprandial hyperglycemia, thereby contributing to the treatment of diabetes. Thus, α -glucosidase inhibitors help to maintain blood glucose levels and can improve diabetic complications. Furthermore, inhibition of α -glucosidase activity may control obesity.
It can be seen that the probiotic Lactobacillus plantarum MY6 strain has the effect of inhibiting a-glucosidase activity, which makes it a potential probiotic for lowering blood glucose and inhibiting obesity.
(6) Lactobacillus plantarum MY6 strain can inhibit Xanthine Oxidase (XOD) activity
The Lactobacillus plantarum MY6 strain cultured to the stationary phase by using the MRS liquid culture medium is expanded and cultured into a new MRS liquid culture medium at a dilution ratio of 1:30, bacterial suspension is collected when the culture is carried out to the stationary phase for 24 hours, fermentation broth supernatant is collected after centrifugation at 10,000Xg and 4 ℃ for 10 minutes, and then the activity of xanthine oxidase in the fermentation broth supernatant is measured by a xanthine oxidase activity measuring kit (box manufacturing process, cat: AKAO M). The results showed that the fermentation supernatant of strain MY6 had a significant inhibition of xanthine oxidase activity compared to the blank medium MRS without inhibition of xanthine oxidase activity with an inhibition rate of 43.75% (< 0.05), indicating that lactobacillus plantarum MY6 can produce and secrete metabolites to inhibit Xanthine Oxidase (XOD) activity during stationary phase (fig. 7).
Xanthine oxidase is a key enzyme in the catabolism of purines, and can catalyze the direct production of uric acid from hypoxanthine and xanthine. Thus, when xanthine oxidase activity is abnormally active in the body, it leads to the production of a large amount of uric acid, thereby causing hyperuricemia or gout.
Xanthine oxidase inhibitors such as allopurinol inhibit xanthine oxidase activity and prevent the metabolism of hypoxanthine and xanthine into uric acid, thereby reducing uric acid production and improving gout and hyperuricemia. Xanthine oxidase inhibitors can also reduce stress response and damage to tissues caused by free radicals, and are expected to be clinically used for treating gout and diseases caused by peroxide free radicals. At present, allopurinol is one of main medicines for treating hyperuricemia and gout, and is the only chemical medicine for inhibiting uric acid generation clinically, but the medicine has a plurality of side effects, can cause fever, allergic rash abdominal pain, diarrhea, leucocyte and thrombocytopenia and multiple organ damage, even has reports of death, and has questioned safety. It has been used until now because of its excellent inhibitory effect on xanthine oxidase. Therefore, the research of new low-toxicity and high-efficiency xanthine oxidase inhibitors is of great significance.
Therefore, the probiotic lactobacillus plantarum MY6 strain is expected to reduce in-vivo purine and uric acid generation by inhibiting the activity of xanthine oxidase, thereby controlling uric acid level and preventing gout flares.
(7) The fermented liquid of the plant lactobacillus MY6 strain can effectively inhibit the activity of renin
Lactobacillus plantarum MY6 cultured with an MRS liquid medium to a stationary phase is expanded and cultured into a new MRS liquid medium at a dilution ratio of 1:30, a bacterial suspension is collected when the culture is carried out to the stationary phase for 24 hours, a fermentation broth supernatant is collected after centrifugation at 10,000×g and 4 ℃ for 10 minutes, and then the renin inhibition capacity of the fermentation broth supernatant is measured by a renin inhibitor screening kit (KA 1361). The results show that the fermentation supernatant of strain MY6 has the ability to inhibit renin compared to the non-inhibitory effect of the blank medium MRS with an inhibition rate of about 24.89% (< 0.05), indicating that the fermentation broth of lactobacillus plantarum MY6 can effectively inhibit renin (fig. 8).
Renin is an aspartic protease of about 40kDa that converts angiotensinogen to angiotensin I. Angiotensin Converting Enzyme (ACE) is a monomeric zinc metalloenzyme found in vascular endothelium that converts angiotensin i to angiotensin ii, which is the final active messenger of the renin-angiotensin system (RAS) pathway. Angiotensin II can inhibit renin secretion by acting directly on glomerular cells. Angiotensin II has many physiological roles, the most important of which is that it can act as a powerful vasoconstrictor, increasing blood pressure by changing the resistance of the surrounding blood vessels. Since renin is the only known renin substrate, cleavage of renin by renin is critical to the ultimate activity of the RAS pathway, inhibition of renin would be an attractive strategy to control hypertension. In addition, renin inhibitors may prevent the formation of angiotensin I and angiogenin. Thus, the effect of renin inhibitors on inhibiting renin activity can be utilized to prevent and treat hypertension and other cardiovascular and renal diseases.
It can be seen that the probiotic lactobacillus plantarum MY6 strain has the ability to inhibit renin, which makes it a potential probiotic for lowering blood pressure and protecting the kidneys.
In summary, the newly isolated lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain of the present invention has various probiotic effects: (1) 3-hydroxybutyric acid may be produced and secreted; (2) inhibits acetylcholinesterase activity; (3) glutathione can be produced and secreted; (4) gamma-aminobutyric acid can be produced and secreted; (5) can inhibit alpha-glucosidase activity; (6) can inhibit xanthine oxidase activity; (7) renin activity can be inhibited. Therefore, the lactobacillus plantarum MY6 strain newly separated and obtained by the invention has important application value and economic value in the fields of anti-inflammatory, bowel relaxing, intestine protecting and the like.
The embodiments of the present invention have been described in detail above, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, and yet fall within the scope of the invention.
Claims (10)
1. Lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain, characterized in that the lactobacillus paracasei MY6 strain was deposited with the chinese collection of typical cultures at day 3, 7, 2023, under the accession number: CCTCC NO: M20231172; the whole sequence of the 16S rDNA of the cheese bacillus MY6 strain is shown in SEQ ID No: 1.
2. Use of the lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain of claim 1 for the preparation of renin inhibitors.
3. Use of the lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain of claim 1 for the production of 3-hydroxybutyric acid.
4. Use of the lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain of claim 1 in the preparation of an acetylcholinesterase inhibitor.
5. Use of the lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain of claim 1 for the production of reduced glutathione.
6. Use of the lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain of claim 1 for the production of gamma-aminobutyric acid.
7. Use of the lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain of claim 1 for the preparation of an alpha-glucosidase inhibitor.
8. Use of the lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain of claim 1 for the preparation of xanthine oxidase inhibitors.
9. A probiotic functional bacterial agent, characterized in that it comprises the lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain of claim 1.
10. The probiotic functional microbial agent of claim 9, wherein the microbial agent is a fermented product of lactobacillus plantarum (Lactiplantibacillus plantarum) MY6 strain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410191790.XA CN117946941A (en) | 2024-02-21 | 2024-02-21 | Lactobacillus plantarum MY6 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410191790.XA CN117946941A (en) | 2024-02-21 | 2024-02-21 | Lactobacillus plantarum MY6 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117946941A true CN117946941A (en) | 2024-04-30 |
Family
ID=90794218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410191790.XA Pending CN117946941A (en) | 2024-02-21 | 2024-02-21 | Lactobacillus plantarum MY6 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117946941A (en) |
-
2024
- 2024-02-21 CN CN202410191790.XA patent/CN117946941A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116555076B (en) | Bifidobacterium longum subspecies longum MY1 and application thereof in preparation of food and medicine for relaxing bowels and protecting intestines | |
| CN116814464A (en) | Fermented lactobacillus mucilaginosus JF5 and application thereof in preparation of lipid-reducing and digestion-aiding foods and medicines | |
| CN113717883B (en) | Lactobacillus plantarum FLPL05 for promoting body health and longevity and application thereof | |
| CN116555075B (en) | Lactobacillus plantarum JF1 and application thereof in preparation of anti-aging food and drug | |
| CN117264840A (en) | Lactobacillus brevis XY8 and application thereof in preparation of food and medicine for resisting aging and improving gout | |
| CN117264839A (en) | Application of saliva combined with lactobacillus MB1 in preparation of food and medicine for whitening and relieving gout | |
| CN117343875A (en) | Lactobacillus gasseri MY5 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and medicine | |
| CN116555074B (en) | Lactobacillus brevis JT1 and application thereof in preparation of hypoglycemic drugs | |
| CN117946941A (en) | Lactobacillus plantarum MY6 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and medicine | |
| CN117363524B (en) | Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines | |
| CN117946938A (en) | Lactobacillus plantarum SM3 and application thereof in preparation of blood sugar reducing and sleep-aiding foods and medicines | |
| CN117946937A (en) | Lactobacillus plantarum XY1 and application thereof in preparation of foods and medicines for reducing blood sugar and improving gout | |
| CN117946939A (en) | Lactobacillus plantarum SM2 and application thereof in preparation of cholesterol-lowering and sleep-aiding foods and medicines | |
| CN117946936A (en) | Lactobacillus plantarum XY4 and application thereof in preparation of digestion-aiding and anti-inflammatory food and drug | |
| CN117946942A (en) | Lactobacillus plantarum MY3 and application thereof in preparing food and medicine for regulating intestines and stomach and improving constipation | |
| CN117721033B (en) | Lactobacillus mucilaginosus KS6 and application thereof in preparation of anti-inflammatory and sleep-aiding foods and medicines | |
| CN117946940A (en) | Lactobacillus plantarum SM1 and application thereof in preparing food and medicine for regulating intestines and stomach and losing weight | |
| CN117384788B (en) | Saliva combined lactobacillus SM4 and application thereof in preparation of whitening and cholesterol lowering foods and medicines | |
| CN117004503B (en) | Saliva combined lactobacillus MB1 and application thereof in preparation of food and medicine for assisting sleep and regulating intestines and stomach | |
| CN116656526B (en) | Lactobacillus plantarum JF4 and application thereof in preparation of blood sugar and cholesterol reducing foods and medicines | |
| CN118146998A (en) | Bifidobacterium longum subspecies longum KS1 and application thereof in preparation of anti-aging and sleep-aiding food and medicine | |
| CN116218733B (en) | Lactobacillus rhamnosus XY5 and application thereof in preparing antiallergic and digestion-promoting food and drug | |
| CN116286519B (en) | Lactobacillus paracasei KS3 and application thereof in preparation of anti-aging and digestion-aiding foods and medicines | |
| CN117286045B (en) | Bifidobacterium longum subspecies longum KS2 and application thereof in preparation of anti-aging medicines | |
| CN117946943A (en) | Application of lactobacillus plantarum JF4 in preparation of uric acid-reducing and anti-aging foods and medicines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |